V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Exelixis Executive Compensation (FY25)

EXEL · Executive and director compensation, fiscal 2023 to 2025
Chief executive, fiscal 2025
◇
Michael Morrissey
Median of the other named officers
$9,784,332
6 officers, excluding the chief executive
Latest say-on-pay support
=
May 26, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Exelixis brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): May 29, 2026
12 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Exelixis brief$1,500Get the executive brief
Velarion Member, one year
343 figures on this page: 334 cited to the filing that reported them, 9 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Michael Morrissey: $12,732,048 → $33,239,183 (161.1% higher)
Say-on-pay support: 96.9% → 79.0% (17.9 points lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Exelixis' chief executive and what were they paid?
Michael Morrissey was paid $33,239,183 in total compensation as President and Chief Executive Officer for fiscal 2025. Morrissey's total was 161.1% higher than the $12,732,048 reported for fiscal 2024.
What was Exelixis' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 79.0% of votes cast including abstentions in favor at the meeting held May 26, 2026.
Which companies are in Exelixis' peer group?
Companies named in the disclosed peer group include ACADIA Pharmaceuticals Inc., Alkermes plc, Alnylam Pharmaceuticals, Inc., Amgen Inc. and Biogen Inc., among others.
What is Exelixis' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 81:1, against median employee compensation of $410,693.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Morrissey
President and Chief Executive Officer
◇—◇—◇—◇◇
Amy Peterson
Former Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
◇◇◇◇◇—◇◇
Dana Aftab
Executive Vice President, Research and Development
◇—◇—◇—◇◇
Christopher Senner
Executive Vice President and Chief Financial Officer
◇—◇—◇—◇◇
Jeffrey Hessekiel
Former Executive Vice President and General Counsel
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Morrissey
President and Chief Executive Officer
◇—◇—◇—◇◇
Christopher Senner
Executive Vice President and Chief Financial Officer
◇—◇—◇—◇◇
Amy Peterson
Former Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
◇—◇—◇—◇◇
Jeffrey Hessekiel
Former Executive Vice President and General Counsel
◇—◇—◇—◇◇
Dana Aftab
Executive Vice President, Research and Development
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Morrissey
President and Chief Executive Officer
◇—◇—◇—◇◇
Amy Peterson
Former Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
Departed during or after this year
◇—◇———◇◇
Christopher Senner
Executive Vice President and Chief Financial Officer
◇—◇—◇—◇◇
Dana Aftab
Executive Vice President, Research and Development
◇—◇—◇—◇◇
Patrick Haley
Executive Vice President, Commercial
◇—◇—◇—◇◇
Jeffrey Hessekiel
Former Executive Vice President and General Counsel
Departed during or after this year
◇—◇———◇◇
Brenda Hefti
Senior Vice President and General Counsel
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Amy C. PetersonPSU◇—◇———◇
Amy C. PetersonPSU◇◇◇—◇—◇
Amy C. PetersonRSU◇——◇——◇
Brenda J. HeftiPSU◇—◇———◇
Brenda J. HeftiRSU◇——◇——◇
Brenda J. HeftiRSU◇——◇——◇
Brenda J. HeftiPSU◇◇◇—◇—◇
Christopher J. SennerPSU◇◇◇—◇—◇
Christopher J. SennerPSU◇—◇———◇
Christopher J. SennerRSU◇——◇——◇
Dana T. AftabRSU◇——◇——◇
Dana T. AftabPSU◇◇◇—◇—◇
Dana T. AftabPSU◇—◇———◇
Dana T. AftabRSU◇——◇——◇
Jeffrey J. HessekielRSU◇——◇——◇
Jeffrey J. HessekielPSU◇◇◇—◇—◇
Jeffrey J. HessekielPSU◇—◇———◇
Michael M. MorrisseyPSU◇—◇———◇
Michael M. MorrisseyPSU◇◇◇—◇—◇
Michael M. MorrisseyRSU◇——◇——◇
Patrick J. HaleyPSU◇—◇———◇
Patrick J. HaleyRSU◇——◇——◇
Patrick J. HaleyPSU◇◇◇—◇—◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Dana AftabRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Patrick HaleyRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Michael MorrisseyRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/3/2028
Christopher SennerRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Brenda HeftiRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Stelios Papadopoulos, Ph.D
Board chair
◇◇————◇
Julie A. Smith
◇◇———◇◇
Jack L. Wyszomierski
◇◇————◇
Maria C. Freire, Ph.D
◇◇———◇◇
Tomas J. Heyman
◇◇———◇◇
George Poste, DVM, Ph.D., FRS
◇◇————◇
Mary C. Beckerle, Ph.D
◇◇———◇◇
David E. Johnson
◇—◇——◇◇
S. Gail Eckhardt, M.D
◇◇———◇◇
Robert L. Oliver Jr
◇◇————◇
Michael M. Morrissey, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Audit committee member◇
Compensation committee member◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals Inc. ACAD
  • Alkermes plc ALKS
  • Alnylam Pharmaceuticals, Inc. ALNY
  • Amgen Inc. AMGN
  • Biogen Inc. BIIB
  • BioMarin Pharmaceutical Inc. BMRN
  • Bristol-Myers Squibb Company BMY
  • Celgene Corporation CELG
  • Eli Lilly and Company LLY
  • Exact Sciences Corporation EXAS
  • Gilead Sciences, Inc. GILD
  • H. Lundbeck A/S LBKAY
  • Halozyme Therapeutics HALO
  • Incyte Corporation INCY
  • Ionis Pharmaceuticals, Inc. IONS
  • Jazz Pharmaceuticals plc JAZZ
  • Johnson & Johnson JNJ
  • Merck & Co., Inc. MRK
  • Natera, Inc. NTRA
  • Neurocrine Biosciences, Inc. NBIX
  • Novartis AG NVS
  • NovoCure Limited NVCR
  • Pfizer Inc. PFE
  • PTC Therapeutics, Inc. PTCT
  • Regeneron Pharmaceuticals, Inc. REGN
  • Sanofi SNY
  • Sarepta Therapeutics, Inc. SRPT
  • Takeda Pharmaceutical Company Limited TAK
  • Ultragenyx Pharmaceutical Inc. RARE
  • United Therapeutics Corporation UTHR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 26, 2026=◇◇◇
2024May 28, 2025=◇◇◇
2023May 30, 2024=◇◇◇
2022May 31, 2023=◇◇◇
2021May 25, 2022=◇◇◇
2020May 26, 2021=◇◇◇
2019May 20, 2020=◇◇◇
2018May 22, 2019=◇◇◇
2017May 23, 2018=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Michael Morrissey (President and Chief Executive Officer), FY2025 total compensation $33,239,183 (base salary $1,306,040) [exec_comp, SEC accession 0000939767-26-000046, filed 2026-04-15]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Exelixis files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Exelixis disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Exelixis sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Exelixis' disclosed peer group is defensible, who names Exelixis back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
343 figures on this page: 334 cited to the filing that reported them, 9 calculated from figures it prints.
334 cited to the filing
9 calculated from the filing

Documents cited

  1. 0000939767-26-000074
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0000939767-26-000046
    CEO Pay Ratio · Director Compensation Table · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year-End · and 1 more section
  3. 0000939767-25-000097
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000939767-25-000061
    Summary Compensation Table
  5. 0000939767-24-000081
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000939767-24-000044
    Summary Compensation Table
  7. 0000939767-23-000069
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0000939767-22-000070
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0000939767-21-000057
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0000939767-20-000089
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0000939767-19-000125
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0000939767-18-000087
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Exelixis executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/EXEL (accessed 2026).
Short form: data: Velarion

The Exelixis brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
12 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Exelixis and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Exelixis discloses

The companies named in EXEL's own disclosed peer group.

ACADIA Pharmaceuticals Inc.Alkermes plcAlnylam Pharmaceuticals, Inc.Amgen Inc.Biogen Inc.BioMarin Pharmaceutical Inc.Bristol-Myers Squibb CompanyEli Lilly and CompanyExact Sciences CorporationGilead Sciences, Inc.Halozyme TherapeuticsIncyte CorporationIonis Pharmaceuticals, Inc.Jazz Pharmaceuticals plcJohnson & JohnsonMerck & Co., Inc.Natera, Inc.Neurocrine Biosciences, Inc.NovoCure LimitedPfizer Inc.PTC Therapeutics, Inc.Regeneron Pharmaceuticals, Inc.Sarepta Therapeutics, Inc.Ultragenyx Pharmaceutical Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy